Liteng Lin
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
- Hepatology 16
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Liver physiology and pathology 5
- Immunology 12
- Immunotherapy and Immune Responses 5
- Co-authors
- Xintao Shuai (13 shared papers)Kangshun Zhu (29 shared papers)Mingyue Cai (27 shared papers)Wensou Huang (26 shared papers)Jingjun Huang (20 shared papers)Yongjian Guo (21 shared papers)Yong Wang (9 shared papers)Licong Liang (15 shared papers)
- Journals
- Biomaterials Science (3 papers)Biomedicine & Pharmacotherapy (3 papers)Nanomedicine Nanotechnology Biology and Medicine (2 papers)Journal of Controlled Release (2 papers)Advanced Healthcare Materials (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Liteng Lin
40 papers receiving 1.2k citations
Liteng Lin's Hit Papers
Peers
Comparison fields: 5 of 90
- Hepatology 303
- Biomaterials 220
- Immunology 268
- Cancer Research 140
- Oncology 205
Countries citing papers authored by Liteng Lin
This map shows the geographic impact of Liteng Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liteng Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liteng Lin more than expected).
Fields of papers citing papers by Liteng Lin
This network shows the impact of papers produced by Liteng Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liteng Lin. The network helps show where Liteng Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Liteng Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 133 | |
| 2 | Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Hit paper breakdown → | 2022 | 128 |
| 3 | 2018 | 102 | |
| 4 | 2020 | 82 | |
| 5 | 2018 | 78 | |
| 6 | 2021 | 77 | |
| 7 | 2022 | 54 | |
| 8 | 2018 | 51 | |
| 9 | 2017 | 50 | |
| 10 | 2021 | 47 | |
| 11 | 2019 | 42 | |
| 12 | Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study | 2022 | 36 |
| 13 | 2023 | 34 | |
| 14 | 2020 | 33 | |
| 15 | 2019 | 33 | |
| 16 | 2021 | 30 | |
| 17 | 2017 | 26 | |
| 18 | 2023 | 21 | |
| 19 | 2023 | 20 | |
| 20 | 2023 | 20 |
About Liteng Lin
Liteng Lin is a scholar working on Hepatology, Immunology, Molecular Biology, Oncology and Biomedical Engineering, having authored 40 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Nanoplatforms for cancer theranostics (8 papers), Cancer Immunotherapy and Biomarkers (6 papers), Liver physiology and pathology (5 papers), Nanoparticle-Based Drug Delivery (5 papers), Immunotherapy and Immune Responses (5 papers), RNA Interference and Gene Delivery (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). The work is most often cited by research in Hepatology (303 citations), Biomaterials (220 citations), Immunology (268 citations), Cancer Research (140 citations) and Oncology (205 citations). Liteng Lin has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Xintao Shuai, Kangshun Zhu, Mingyue Cai, Wensou Huang, Jingjun Huang, Yongjian Guo, Yong Wang, Licong Liang, Zecong Xiao and Xiaoyan Chen. Their work appears in journals such as Biomaterials Science, Biomedicine & Pharmacotherapy, Nanomedicine Nanotechnology Biology and Medicine, Journal of Controlled Release and Advanced Healthcare Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.